WallStSmart
LRMR

Larimar Therapeutics Inc

NASDAQ: LRMR · HEALTHCARE · BIOTECHNOLOGY

$4.06
-6.45% today

Updated 2026-04-30

Market cap
$461.24M
P/E ratio
P/S ratio
EPS (TTM)
$-2.27
Dividend yield
52W range
$2 – $6
Volume
5.0M

Larimar Therapeutics Inc (LRMR) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item201120122013201420152016201720182019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$4000.00$11000.00$12000.00$70000.00$212000.00$188000.00$261000.00$78000.00$155000.00$326000.00$272000.00$311000.00$318000.00$350000.00
Gross profit$-4000.00$-11000.00$-12000.00$-70000.00$-212000.00$-188000.00$-261000.00$-78000.00$-155000.00$-326000.00$-272000.00$-311000.00$-318000.00$-350000.00
Gross margin
R&D$11.40M$11.54M$9.56M$27.39M$54.62M$39.77M$41.74M$49.53M$20.79M$31.41M$38.40M$24.25M$27.67M$73.28M$154.22M
SG&A$8.14M$19.20M$18.29M$12.16M$1.52M$2.42M$11.40M$12.07M$12.28M$14.09M$17.61M$18.27M
Operating income$-13.15M$-13.79M$-13.78M$-35.53M$-73.81M$-57.12M$-53.88M$-62.72M$-23.21M$-42.80M$-50.47M$-36.53M$-41.76M$-90.89M$-172.50M
Operating margin
EBITDA$-13.15M$-13.77M$-14.02M$-35.53M$-73.41M$-57.44M$-52.58M$-60.81M$-23.14M$-42.65M$-50.14M$-36.21M$-41.45M$-90.57M$-172.50M
EBITDA margin
EBIT$-13.16M$-13.78M$-14.03M$-35.53M$-73.48M$-57.65M$-52.76M$-61.07M$-23.21M$-42.80M$-50.47M$-36.53M$-41.76M$-90.89M$-172.85M
Interest expense$97000.00$870000.00$806000.00$347000.00$971000.00$246000.00$1.77M$0.00$326000.00$318000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-13.16M$-13.88M$-14.03M$-36.57M$-74.29M$-57.88M$-52.03M$-61.37M$-23.13M$-42.33M$-50.31M$-34.18M$-36.95M$-80.60M$-165.67M
Net income growth (YoY)-5.5%-1.1%-160.7%-103.1%+22.1%+10.1%-18.0%+62.3%-83.0%-18.9%+32.1%-8.1%-118.1%-105.5%
Profit margin